Description:
A combination that exhibits strong activity against highly resistant bacteria, including those resistant to carbapenems.

Text:
In 
particular, the combination of ceftazidimeavibactam (FDA approved in 2015) has 
emerged as a promising solution, with both classified as critically important by the 
WHO.3 This combination exhibits strong activity against highly resistant bacteria, 
including those resistant to carbapenems.4,5 However, the identification of variants of 
different lactamases has raised uncertainties regarding the future effectiveness of this 
treatment strategy.
